Navigenics, a leading personal genomics company, announced today that
the company has raised approximately $18 million of funding. The Procter
and Gamble Company, with a worldwide portfolio of leading consumer
brands, has joined existing Navigenics investors Kleiner Perkins
Caufield and Byers and Mohr Davidow Ventures who also participated in
this financing round.
“I welcome the partnership of Procter and Gamble. Their extraordinary
track record of consumer understanding provides Navigenics with an
unparalleled opportunity to understand and serve the needs of our
customers”
“I welcome the partnership of Procter and Gamble. Their extraordinary
track record of consumer understanding provides Navigenics with an
unparalleled opportunity to understand and serve the needs of our
customers,” said Vance Vanier, MD, Navigenics President and CEO. “When
combined with their commitment to developing innovative consumer health
and wellness products and an expanding focus on health services, P&G’s
insight and brand will strengthen Navigenics’ position to embed personal
genomics into the prevention dialogue of everyday health care.”
“Navigenics represents an exciting opportunity for future innovation for
P&G,” said Nathan Estruth, Vice President of Procter & Gamble
FutureWorks and Board member of MDVIP, a national network of primary
care physicians focused on personalized, preventive care. MDVIP has
initiated a collaborative effort with Navigenics, making their genetic
test available as a service to MDVIP-affiliated physicians. “Based on
their strong science and clinical foundation, Navigenics promises to
change the shape of health care as we know it. Personalized genetic
testing can have significant meaning in helping consumers focused on
prevention and wellness live better, healthier lives – something that
P&G has always been committed to.”
“This Series C financing will help ensure that Navigenics has the
ability to continue our groundbreaking research into the impact of
genomics on preventive health care, expand our clinical offerings into
exciting new areas and lead the way in making personal genomics an
integral part of employer-sponsored preventive health and wellness
programs,” said Dr. Vanier.